Arden Trust’s Kyntra Bio KYNB Stock Holding History

Arden Trust’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-133	Closed	-$115K	–	481
2020 Q1	$115K	Buy	+133	New	+$132K	0.02%	364

Other funds holding KYNB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Arden Trust's KYNB Position: Q2 2020 in Review

Arden Trust sold out of Kyntra Bio (KYNB) in Q2 2020, closing a stake of 133 shares — an estimated $115K sold.

Arden Trust first reported a position in KYNB in Q1 2020 and held it in 1 quarter. The position peaked at $115K in Q1 2020. 194 funds tracked by Wall St. Rank hold KYNB as of Q2 2020.

Arden Trust reported no remaining Kyntra Bio position as of Q2 2020 after selling out during the quarter.
Arden Trust sold 133 Kyntra Bio shares in Q2 2020, an estimated $115K.
Arden Trust first reported a position in Kyntra Bio in Q1 2020 and held it in 1 quarter.
Arden Trust's Kyntra Bio position peaked at $115K in Q1 2020.
194 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2020.

Based on Arden Trust's 13F filing for Q2 2020, filed 9 Jul 2020.